Session IV: Novel Targets

Novel Targets

The central theme for session IV at the Myeloma2018 meeting was novel drug targets for MM targets. Nizar Bahlis, MD, and Enrique Ocio, MD, PhD, identify MCL-1 as a possible target in MM, indicating a potential niche for MCL-1 inhibitors. Leif Bergsagel, MD, Robert Orlowski, MD, PhD, and Keith Stewart, MBChB, explore further drug targets.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter